| [1] |
Humphreys BD. Mechanisms of renal fibrosis [J]. Annu Rev Physiol, 2018, 80: 309-326.
|
| [2] |
Nistor I, De Sutter J, Drechsler C, et al. Effect of renin－angiotensin－aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta－analysis [J]. Nephrol Dial Transplant, 2017, 33(1): 12-22.
|
| [3] |
Liu BC, Tang TT, Lv LL, et al. Renal tubule injury: a driving force toward chronic kidney disease [J]. Kidney Int, 2018, 93(3): 568-579.
|
| [4] |
Tang PMK, Nikolic－Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis [J]. Nat Rev Nephrol, 2019, 15(3): 144-158.
|
| [5] |
Ikezumi Y, Suzuki T, Karasawa T, et al. Identification of alternatively activated macrophages in new－onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion [J]. Histopathology, 2011, 58(2): 198-210.
|
| [6] |
Eardley KS, Kubal C, Zehnder D, et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease [J]. Kidney Int, 2008, 74(4): 495-504.
|
| [7] |
de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140－B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial [J]. Lancet Diabetes Endocrinol, 2015, 3(9): 687-696.
|
| [8] |
Han H, Zhu J, Wang Y, et al. Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction [J]. J Pathol, 2017, 241(1): 80-90.
|
| [9] |
Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6－month trial with extended follow－up [J]. J Am Soc Nephrol, 2017, 28(1): 348-358.
|
| [10] |
Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction [J]. J Am Soc Nephrol, 2017, 28(4): 1306-1313.
|
| [11] |
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study [J]. Arthritis Rheum, 2012, 64(4): 1215-1226.
|
| [12] |
Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT－2 inhibitor dapagliflozin on glomerular and tubular injury markers [J]. Diabetes Obes Metab, 2018, 20(8): 1988-1993.
|
| [13] |
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]. N Engl J Med, 2019, 380(24): 2295-2306.
|
| [14] |
Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease [J]. Kidney Int, 2014, 86(5): 896-904.
|
| [15] |
Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria [J]. J Am Soc Nephrol, 2009, 20(3): 655-664.
|
| [16] |
Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy [J]. J Am Soc Nephrol, 2010, 21(3): 527-535.
|
| [17] |
Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double－blind, randomised, placebo－controlled trial [J]. Lancet, 2019, 393(10184): 1937-1947.
|
| [18] |
Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy [J]. J Am Soc Nephrol, 2011, 22(6): 1144-1151.
|
| [19] |
Vincenti F, Fervenza FC, Campbell KN, et al. A phase 2, double－blind, placebo－controlled, randomized study of fresolimumab in patients with steroid－resistant primary focal segmental glomerulosclerosis [J]. Kidney Int Rep, 2017, 2(5): 800-810.
|
| [20] |
Voelker J, Berg PH, Sheetz M, et al. Anti－TGF－beta1 antibody therapy in patients with diabetic nephropathy [J]. J Am Soc Nephrol, 2017, 28(3): 953-962.
|
| [21] |
Ramazani Y, Knops N, Elmonem MA, et al. Connective tissue growth factor (CTGF) from basics to clinics [J]. Matrix Biol, 2018, 68－69: 44-66.
|
| [22] |
Adler SG, Schwartz S, Williams ME, et al. Phase 1 study of anti－CTGF monoclonal antibody in patients with diabetes and microalbuminuria [J]. Clin J Am Soc Nephrol, 2010, 5(8): 1420-1428.
|
| [23] |
Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease [J]. Nat Rev Dis Primers, 2017, 3: 17088.
|
| [24] |
Heerspink HJL, Persson F, Brenner BM, et al. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial [J]. Lancet Diabetes Endocrinol, 2016, 4(4): 309-317.
|
| [25] |
Chen YM, Chiang WC, Lin SL. Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update [J]. J Biomed Sci, 2017, 24(1): 84.
|
| [26] |
Perkins RM, Aboudara MC, Uy AL, et al. Effect of pentoxifylline on GFR decline in CKD: a pilot, double－blind, randomized, placebo－controlled trial [J]. Am J Kidney Dis, 2009, 53(4): 606-616.
|
| [27] |
Navarro－Gonzalez JF, Mora－Fernandez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial [J]. J Am Soc Nephrol, 2015, 26(1): 220-229.
|
| [28] |
Leporini C, Pisano A, Russo E, et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta－analysis [J]. Pharmacol Res, 2016, 107: 315-332.
|
| [29] |
Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long－term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP－1 [J]. J Diabetes Res, 2013, 2013: 489869.
|
| [30] |
Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study [J]. Diabetologia, 2011, 54(2): 280-290.
|
| [31] |
Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease [J]. Diabetologia, 2016, 59(8): 1624-1627.
|
| [32] |
Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency [J]. Am J Kidney Dis, 2019, 75(1): 84-104.
|